Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
Exxon Mobil
XOM
|
+$267M |
| 2 |
Chevron
CVX
|
+$202M |
| 3 |
Tesla
TSLA
|
+$201M |
| 4 |
NVIDIA
NVDA
|
+$182M |
| 5 |
Pfizer
PFE
|
+$123M |
Top Sells
| 1 |
Apple
AAPL
|
+$270M |
| 2 |
First Solar
FSLR
|
+$147M |
| 3 |
Walmart
WMT
|
+$138M |
| 4 |
Steel Dynamics
STLD
|
+$123M |
| 5 |
Reliance Steel & Aluminium
RS
|
+$117M |
Sector Composition
| 1 | Technology | 17.96% |
| 2 | Financials | 15.55% |
| 3 | Industrials | 13.45% |
| 4 | Consumer Discretionary | 11.05% |
| 5 | Healthcare | 10.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3126
Design Therapeutics
DSGN
$349M
| $375K | ﹤0.01% |
59,635
-16,850
| -22% | -$106K |
|
3127
Sandstorm Gold
SAND
$3.4B
| $368K | ﹤0.01% |
71,825
-15,928
| -18% | -$81.6K |
|
3128
United Bancorp
UBCP
$84.8M
| $368K | ﹤0.01% |
30,801
| – | – |
|
3129
NetSol Technologies
NTWK
$49.4M
| $365K | ﹤0.01% |
154,862
-59,516
| -28% | -$140K |
|
3130
Annovis Bio
ANVS
$45M
| $361K | ﹤0.01% |
25,251
| – | – |
|
|
SPPI
3131
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $357K | ﹤0.01% |
371,752
-40
| -0% | -$38 |
|
|
PTRA
3132
DELISTED
Proterra Inc. Common Stock
PTRA
| $353K | ﹤0.01% |
294,105
-255,868
| -47% | -$307K |
|
|
OKUR
3133
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$33.8M
| $351K | ﹤0.01% |
5,353
+1,651
| +45% | +$108K |
|
|
MRNS
3134
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $348K | ﹤0.01% |
32,089
| – | – |
|
|
OGI
3135
Organigram Holdings
OGI
$221M
| $347K | ﹤0.01% |
222,631
-26,433
| -11% | -$41.2K |
|
3136
Atea Pharmaceuticals
AVIR
$250M
| $345K | ﹤0.01% |
92,351
+30,712
| +50% | +$115K |
|
|
ENFN
3137
DELISTED
Enfusion, Inc.
ENFN
| $340K | ﹤0.01% |
+30,291
| New | +$340K |
|
3138
Bank First Corp
BFC
$1.26B
| $339K | ﹤0.01% |
4,079
| – | – |
|
3139
Pixelworks
PXLW
$61.5M
| $337K | ﹤0.01% |
16,226
-16,174
| -50% | -$336K |
|
|
CAMP
3140
DELISTED
CalAmp Corp.
CAMP
| $336K | ﹤0.01% |
13,784
-4,945
| -26% | -$121K |
|
3141
CF Bankshares
CFBK
$163M
| $333K | ﹤0.01% |
21,939
+846
| +4% | +$12.9K |
|
3142
Acumen Pharmaceuticals
ABOS
$81.8M
| $332K | ﹤0.01% |
68,979
+2,200
| +3% | +$10.6K |
|
3143
Paysign
PAYS
$281M
| $330K | ﹤0.01% |
134,849
+89,461
| +197% | +$219K |
|
3144
ImmuCell
ICCC
$55.7M
| $328K | ﹤0.01% |
64,264
-425
| -0.7% | -$2.17K |
|
3145
Solid Biosciences
SLDB
$408M
| $326K | ﹤0.01% |
62,164
+5,829
| +10% | +$30.5K |
|
|
SSBK
3146
DELISTED
Southern States Bancshares
SSBK
| $325K | ﹤0.01% |
15,383
+4,915
| +47% | +$104K |
|
3147
Workiva
WK
$4.24B
| $318K | ﹤0.01% |
+3,128
| New | +$318K |
|
3148
Telos
TLS
$469M
| $318K | ﹤0.01% |
124,040
-152,841
| -55% | -$391K |
|
|
FORTY
3149
Formula Systems
FORTY
$2.22B
| $316K | ﹤0.01% |
4,303
| – | – |
|
3150
NextCure
NXTC
$14.7M
| $315K | ﹤0.01% |
14,578
-2,524
| -15% | -$54.5K |
|